Amarin Corp Plc (AMRN)

[ziploc_1]

Amarin and Moshida agreed to "collaborate" on new products in 2020...including Amarin's marketing Mochida products in the U.S. and elsewhere...but not in Japan.


Quote from Amarin at he time...'We exercised certain rights under the agreement, resulting in payments of $1.0 million in each of January 2020 and December 2020, respectively, to Mochida.

We have never been informed about what royalties, if any, are to be paid by Amarin to Mochida for new products as a part of this agreement.

The new version of EPA by Mochida, which can deliver EPA, which is better absorbed in the bloodstream of patients and can thus be delivered in smaller doses and less frequently than Vascepa while having the same anti-inflammatory effects and reduction of CVD...puts the question of the economic feasibility for Amarin marketing this new product in the U.S. into focus.

Amarin has never capitalized on this agreement with Mochida...The time may have come.